Dipeptidyl peptides inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1325-1334

  Wesley, Urnadevi V ^a   McGroarty, Michelle ^a   Homoyouni, Asal ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DIPEPTIDYL PEPTIDASE IV; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; UROKINASE; ADENOSINE DEAMINASE; DPP4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GLYCOPROTEIN;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL CYCLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; CELL NUCLEUS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOSINE DEAMINASE; ANTIGENS, CD26; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; FIBRONECTINS; GLYCOPROTEINS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; URINARY PLASMINOGEN ACTIVATOR;

EID: 13944249137     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1852     Document Type: Article

References (50)

1. Ware JL. Growth factor network disruption in prostate cancer progression. Cancer Metastasis Rev 1998-1999;17:443-7.
2. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-71.
3. Dow JK, deVere White RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000;55:800-6.
4. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10:26-7.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992;52:571-7.
7. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73.
8. Proost P, Struyt S, Schols D, et al. Truncation of Macrophage-derived Chemokines by CD26/dipeptidyl peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-93.
9. Bauvois BA. Collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem J 1988;252:723-31.
10. Piazza GA, Callanan HM, Mowery J, Hixson DC. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem J 1989;262:327-34.
11. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999;190:311-22.
12. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004;109:855-66.
13. Sedo A, Kraml J. Dipeptidyl peptidase IV in cell proliferation and differentiation. Sb Lek 1994;95:285-8.
14. Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ, Eisinger M. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med 1988;167:197-212.
15. Abbott CA, Gorrell MD, Levy MT, McCaughan GW. Molecular analyses of human and rat dipeptidyl peptidase IV. Adv Exp Med Biol 1997;421:161-9.
16. Bogenrieder T, Finstad CL, Freeman RH, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997;33:225-32.
17. Dingens WNM, TenKate J, Kirch JM, et al. Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas. J Pathol 1999;160:195-201.
18. Sakamoto J, Watanabe T, Teramukai S, et al. Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies. J Surg Oncol 1993;52:124-34.
19. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
20. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanisms. FEBS Lett 2000;18:468:6-10.
21. Bugler B, Amalric F, Prats H. Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 1991;11:573-7.
22. Okada-Ban M, Moens G, Thiery JP, Jouanneau J. Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene 1999;18:6719-24.
23. Fukui S, Otani N, Nawashiro H, et al. Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol 2002;57:221-9.
24. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawar MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304-11.
25. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61:2533-6.
26. Cronauer MV, Hittmair A, Eder IE, et al. Basic fibroblast growth factor levels in cancer cells a and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997;31:223-33.
27. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003;63:5754-60.
28. Pintucci G, Moscatelli D, Saponara F, et al. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 2002;16:598-600.
29. Gaubert F, Escaffit F, Bertrand C, et al. Expression of the high molecular weight fibroblast growth factor-2 isoform of 210 amino acids is associated with modulation of protein kinases Cδ and epsilon and ERK activation. J Biol Chem 2001;276:1545-54.
30. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162:1537-42.
31. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;15:59:279-84.
32. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001;10:393-415.
33. Giuliani R, Bastaki M, Coltrini D, Presta M. Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. J Cell Sci 1999;112:2597-606.
34. Hienert G, Kirchheimer JC, Pfluger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988;140:1466-9.
35. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 2004;59:167-76.
36. Forbes K, Gillette K, Kelley LA, Sehgal I. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis. World J Urol 2004;22:67-71.
37. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 1997;30:58-64.
38. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
39. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12;
40. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;15;21:274-81.
41. Wang X, An Z, Geller J, Hoffman RM. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP. Prostate 1999;15:39:182-6.
42. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997;15;31:168-74.
43. Ganju RK, Sunday M, Tsarwhas DG, Card A, Shipp MA. CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. J Clin Invest 1994;94:1784-91.
44. Cohen AJ, Bunn PA, Franklin W, et al. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996;15:56:831-9.
45. Sumitomo M, Iwase A, Zheng R, et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004;5:67-78.
46. Shankland SJ, Pippin J, Flanagan M, et al. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 1997;51:1088-99.
47. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kipl). J Clin Invest 1999;103:597-604.
48. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001 Dec 5;93:1783-90.
49. Akamatsu H, Ichihara-Tanaka K, Ozono K, Kamiike W, Matsuda H, Sekiguchi K. Suppression of transformed phenotypes of human fibrosarcoma cells by over-expression of recombinant fibronectin. Cancer Res 1996;56:4541-6.
50. Brenner KA, Corbett SA, Schwarzbauer JE. Regulation of fibronectin matrix assembly by activated Ras in transformed cells. Oncogene 2000 Jun 29;19:156-63.